Implantable cardioverter defibrillator improves survival in patients with heart failure


School of Medicine and Dentistry at the University of Rochester Medical Center


Arthur J. Moss, M.D., Bradford C. Berk, M.D., Ph.D. Distinguished Professor of Cardiology, University of Rochester School of Medicine and Dentistry


Moss led the MADIT (Multicenter Automatic Defibrillator Implantation Trial) series of trials that demonstrated that preventive therapy with an implantable cardioverter defibrillator or ICD – a device that detects potentially fatal arrhythmias and shocks the heart back into a normal rhythm – significantly reduces the risk of death in heart attack survivors. This finding changed medical guidelines nationwide and led to the use of ICDs in millions of patients.


The finding that ICDs reduce death and increase survival was published in the New England Journal of Medicine in 2002.